David Medical(300314)

Search documents
戴维医疗收盘下跌2.62%,滚动市盈率105.19倍,总市值43.89亿元
Sou Hu Cai Jing· 2025-08-13 09:30
Core Viewpoint - David Medical's stock closed at 15.24 yuan, down 2.62%, with a rolling PE ratio of 105.19 times, significantly higher than the industry average of 57.48 times [1][2] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, warming devices, jaundice treatment equipment, and various monitoring devices [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and has been awarded "Zhejiang Province Famous Trademark" and "AAA Credit Rating Enterprise" [1] Financial Performance - In the latest quarterly report for Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The sales gross margin for the same period was 57.13% [2] Industry Comparison - David Medical ranks 105th in terms of PE ratio within the medical device industry, where the median PE ratio is 40.95 times [1][2] - The industry average PE ratio is 57.48 times, indicating that David Medical's valuation is significantly above the industry norms [2]
戴维医疗收盘上涨2.62%,滚动市盈率108.02倍,总市值45.07亿元
Sou Hu Cai Jing· 2025-08-12 09:17
最新一期业绩显示,2025年一季报,公司实现营业收入1.21亿元,同比-22.00%;净利润2256.77万元, 同比-40.78%,销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗108.0278.713.7845.07亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿5振德医疗 17.3716.371.1063.04亿6奥美医疗17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱 18.7518.761.5540.40亿9维力医疗18.7920.082.3644.05亿10奥泰生物19.3120.361.5661.58亿11鱼跃医疗 20.2319.842.73358.29亿12安图生物21.1920.232.72241.60亿 8月12日,戴维医疗今日收盘1 ...
戴维医疗:产品取得注册证
Mei Ri Jing Ji Xin Wen· 2025-08-12 08:34
Group 1 - David Medical (SZ 300314, closing price: 15.65 yuan) announced on August 12 that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Devices Co., Ltd., has recently received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a product named "Disposable Multi-channel Single-port Laparoscopic Puncture Device" [2] - For the year 2024, David Medical's revenue composition is as follows: 98.08% from the medical device manufacturing industry and 1.92% from other businesses [2]
戴维医疗子公司产品获得医疗器械注册证
Zhi Tong Cai Jing· 2025-08-12 08:08
戴维医疗(300314)(300314.SZ)发布公告,公司全资子公司宁波维尔凯迪医疗器械有限公司于近日收 到浙江省药品监督管理局颁发的1项《医疗器械注册证》,产品名称:一次性使用多通道单孔腹腔镜穿 刺器。 一次性使用多通道单孔腹腔镜穿刺器在传统的多孔腹腔镜技术上加以改进,在产品上设计有两个以上器 械通道供手术操作,从而以单个切口替代多个切口完成手术,是一种向更小、更隐蔽创口发展的新型产 品。本产品的使用能够减少手术切口部位,加快患者术后恢复速度,有效降低手术疤痕对美观的影响, 具有较好的应用前景。 ...
戴维医疗(300314.SZ)子公司产品获得医疗器械注册证
智通财经网· 2025-08-12 08:05
Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weier Kaidi Medical Devices Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a new product: a disposable multi-channel single-port laparoscopic puncture device [1] Group 1 - The new device improves upon traditional multi-port laparoscopic technology by incorporating two or more instrument channels for surgical operations, allowing surgeries to be performed through a single incision instead of multiple incisions [1] - This product aims to reduce the number of surgical incision sites, accelerate patient recovery post-surgery, and effectively minimize the aesthetic impact of surgical scars, indicating a promising application outlook [1]
戴维医疗(300314) - 关于全资子公司产品获得医疗器械注册证的公告
2025-08-12 07:42
一、医疗器械注册证的具体情况 产品名称:一次性使用多通道单孔腹腔镜穿刺器 型号、规格:PDA-60-201、PDA-60-301、PDA-60-202、PDA-60-103、 PDA-80-201、PDA-80-301、PDA-80-202、PDA-80-103、PDB-60-220、 PDB-60-202、PDC-35-120、PDC-35-210、PDC-35-102、PDC-35-201 注册证编号:浙械注准20252021581 批准日期:2025年8月8日 证券代码:300314 证券简称:戴维医疗 公告编号:2025-039 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司(以下简称"公司")全资子公司宁 波维尔凯迪医疗器械有限公司于近日收到浙江省药品监督管理局颁发的1 项《医疗器械注册证》,具体如下: 以上产品医疗器械注册证的取得,有利于丰富公司产品线,进一步提 高公司的核心竞争力,对公司未来的经营成果将产生积极影响。 四、风险提示 目前尚无法预 ...
脑机接口商业化起航:三地公布医疗服务价格 多个股年内股价翻倍
Bei Ke Cai Jing· 2025-08-11 14:49
Group 1 - The brain-computer interface (BCI) concept stocks have been active, with multiple stocks rising significantly, and several exceeding 100% increase in price year-to-date [1][3][4] - A recent policy document issued by seven government departments aims to accelerate the BCI industry's development, proposing 17 specific measures to enhance hardware and software capabilities, application of technological achievements, and support for innovation [2][4] - The document outlines a roadmap for BCI development, with milestones set for 2025 and 2027, including the establishment of a comprehensive support system and the cultivation of leading enterprises [5][6] Group 2 - The policy encourages various application scenarios, including industrial manufacturing, healthcare, and consumer applications, aiming to break down departmental barriers and enhance collaboration across the industry [7][8] - The BCI industry is transitioning from research to commercialization, with significant advancements in non-invasive technologies and ongoing efforts to develop core components domestically [8][9] - The medical sector is identified as the fastest-growing area for BCI commercialization, with a projected global market size of $40 billion by 2030, driven by the treatment of central nervous system diseases [9][10] Group 3 - Recent developments include the establishment of pricing for BCI medical services, with specific costs outlined for invasive and non-invasive procedures, providing a foundation for clinical application [12][13] - Several listed companies are actively engaging in the BCI sector, with ongoing research and product development in invasive and semi-invasive BCI applications [13][15] - Companies are also preparing to establish funds and partnerships to support innovation and investment in the BCI field, indicating a strong interest in the sector's growth [14][15]
戴维医疗收盘上涨10.03%,滚动市盈率105.26倍,总市值43.92亿元
Sou Hu Cai Jing· 2025-08-11 09:39
8月11日,戴维医疗今日收盘15.25元,上涨10.03%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到105.26倍,创388天以来新低,总市值43.92亿元。 最新一期业绩显示,2025年一季报,公司实现营业收入1.21亿元,同比-22.00%;净利润2256.77万元, 同比-40.78%,销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗105.2676.703.6843.92亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物1 ...
医疗器械行业11日主力净流出4.97亿元,安杰思、科华生物居前
Sou Hu Cai Jing· 2025-08-11 07:52
来源:金融界 主力资金净流出居前的分别为安杰思(1536.17万元)、科华生物(1457.06万元)、海利生物(1440.72 万元)、华大基因(1419.47万元)、福瑞股份(1329.15万元)。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日,医疗器械行业上涨1.65%,今日主力资金流出4.97亿元,成分 ...
脑机接口板块大幅上涨3.02%
Mei Ri Jing Ji Xin Wen· 2025-08-11 06:47
Group 1 - The brain-computer interface sector experienced a significant increase of 3.02% on August 11 [1] - Among the constituent stocks, Sainuo Medical reached the daily limit increase [1] - David Medical rose by 11.98%, Optoelectronic Co. increased by 7.27%, Innovative Medical grew by 6.53%, and Kunlun Wanwei saw a rise of 4.93% [1]